不同脂溶性氟喹诺酮类药物在 Calu-3 肺上皮细胞模型中主动介导转运和被动扩散的相对贡献。
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
机构信息
INSERM, ERI-23, Pôle Biologie Santé, 40 avenue du Recteur Pineau, 86000 Poitiers, France.
出版信息
Antimicrob Agents Chemother. 2010 Jan;54(1):543-5. doi: 10.1128/AAC.00733-09. Epub 2009 Oct 12.
Abstract
The transport characteristics of six fluoroquinolones (FQs) with various lipophilicities were compared in a Calu-3 cell model. For each FQ, an active polarized transport was observed in the direction of the apical side. However, the apparent permeability of FQs resulted from active transport and passive diffusion that were highly variable between compounds and mainly governed by lipophilicity. Therefore, active transport was predominant for compounds with relatively low lipophilicity but minor for FQs with higher lipophilicity.
摘要
比较了六种脂溶性不同的氟喹诺酮类药物（FQs）在 Calu-3 细胞模型中的转运特性。对于每种 FQ，均观察到朝向顶端的主动极化转运。然而，FQs 的表观渗透性来自于主动转运和被动扩散，这在化合物之间差异很大，主要由脂溶性决定。因此，主动转运对于相对低脂溶性的化合物占主导地位，但对于脂溶性较高的 FQs 则占次要地位。
相似文献
1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.不同脂溶性氟喹诺酮类药物在 Calu-3 肺上皮细胞模型中主动介导转运和被动扩散的相对贡献。
Antimicrob Agents Chemother. 2010 Jan;54(1):543-5. doi: 10.1128/AAC.00733-09. Epub 2009 Oct 12.
2
P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.P-糖蛋白介导的莫西沙星在Calu-3肺上皮细胞模型中的转运
Antimicrob Agents Chemother. 2009 Apr;53(4):1457-62. doi: 10.1128/AAC.01253-08. Epub 2009 Feb 2.
3
Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).在人支气管-气管上皮细胞（Calu-3）中，P-糖蛋白介导氟尼缩松从顶端到基底外侧转运的证据。
Br J Pharmacol. 2001 Dec;134(7):1555-63. doi: 10.1038/sj.bjp.0704390.
4
5
Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats.Calu-3人支气管上皮细胞的通透性特征：体外-体内相关性以预测大鼠肺部吸收情况
J Drug Target. 2002 Feb;10(1):31-40. doi: 10.1080/10611860290007504.
6
Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model.主动介导的氯霉素和噻苯咪唑在 Calu-3 肺上皮细胞模型中的转运。
J Pharm Sci. 2018 Apr;107(4):1178-1184. doi: 10.1016/j.xphs.2017.11.021. Epub 2017 Dec 5.
7
Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model.环丙沙星通过 Calu-3 气道上皮细胞模型被主动转运至支气管肺上皮细胞中。
Antimicrob Agents Chemother. 2013 Jun;57(6):2535-40. doi: 10.1128/AAC.00306-13. Epub 2013 Mar 18.
8
In vitro biopharmaceutical evaluation of ciprofloxacin/metal cation complexes for pulmonary administration.环丙沙星/金属阳离子复合物用于肺部给药的体外生物药剂学评价
Eur J Pharm Sci. 2017 Jan 15;97:92-98. doi: 10.1016/j.ejps.2016.11.011. Epub 2016 Nov 15.
9
Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.加替沙星与外排转运蛋白的相互作用：耐药的可能机制。
Int J Pharm. 2010 Aug 16;395(1-2):114-21. doi: 10.1016/j.ijpharm.2010.05.027. Epub 2010 May 24.
10
Transport characteristics of fexofenadine in the Caco-2 cell model.非索非那定在Caco-2细胞模型中的转运特性。
Pharm Res. 2004 Aug;21(8):1398-404. doi: 10.1023/b:pham.0000036913.90332.b1.
引用本文的文献
1
Predicting Maternal and Infant Tetrahydrocannabinol Exposure in Lactating Cannabis Users: A Physiologically Based Pharmacokinetic Modeling Approach.预测哺乳期大麻使用者母婴四氢大麻酚暴露情况：基于生理药代动力学建模方法
Pharmaceutics. 2023 Oct 14;15(10):2467. doi: 10.3390/pharmaceutics15102467.
2
In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations.可吸入环丙沙星缓释制剂的体外和体内评价
Pharmaceutics. 2023 Sep 6;15(9):2287. doi: 10.3390/pharmaceutics15092287.
3
Physiologically Based Modelling Framework for Prediction of Pulmonary Pharmacokinetics of Antimicrobial Target Site Concentrations.基于生理学的抗菌药物靶部位浓度肺部药代动力学预测模型框架。
Clin Pharmacokinet. 2022 Dec;61(12):1735-1748. doi: 10.1007/s40262-022-01186-3. Epub 2022 Nov 19.
4
Pharmacokinetic herb-drug interactions: Altered systemic exposure and tissue distribution of ciprofloxacin, a substrate of multiple transporters, after combined treatment with Buch.-Ham. ex D. Don extracts.药代动力学方面的草药-药物相互作用：与布氏千里光（Buch.-Ham. ex D. Don）提取物联合治疗后，多种转运蛋白底物环丙沙星的全身暴露和组织分布发生改变。
Front Pharmacol. 2022 Oct 25;13:1033667. doi: 10.3389/fphar.2022.1033667. eCollection 2022.
5
Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.通过新型 PBPK 模型预测口服吸入药物的区域性呼吸组织和全身浓度。
Drug Metab Dispos. 2022 May;50(5):519-528. doi: 10.1124/dmd.121.000789. Epub 2022 Mar 4.
6
Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate.磷酸奥司他韦前药（奥司他韦膦酸）经雾化或静脉给药后在大鼠肺部的药代动力学
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00074-19. Print 2019 Jun.
7
Mechanistic Study of the Distribution of Lascufloxacin into Epithelial Lining Fluid.拉司氟沙星向黏膜衬液分布的作用机制研究。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02208-18. Print 2019 Apr.
8
Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters.新型高效结核分枝杆菌拓扑异构酶 I 抑制剂的特性及其与人 ABC 多药转运蛋白的相互作用。
PLoS One. 2018 Sep 5;13(9):e0202749. doi: 10.1371/journal.pone.0202749. eCollection 2018.
9
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate.大鼠雾化抗菌药物的生物制药特性：5. 奥司他韦羧酸盐。
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5085-7. doi: 10.1128/AAC.00909-16. Print 2016 Aug.
10
Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam.大鼠雾化抗菌药物的生物制药特性。4. 氨曲南。
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3196-8. doi: 10.1128/AAC.00165-16. Print 2016 May.
本文引用的文献
1
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.左氧氟沙星吸入溶液气雾剂MP - 376在铜绿假单胞菌引起的小鼠肺部感染模型中的疗效。
Antimicrob Agents Chemother. 2009 Sep;53(9):3923-8. doi: 10.1128/AAC.00268-09. Epub 2009 Jun 15.
2
P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.P-糖蛋白介导的莫西沙星在Calu-3肺上皮细胞模型中的转运
Antimicrob Agents Chemother. 2009 Apr;53(4):1457-62. doi: 10.1128/AAC.01253-08. Epub 2009 Feb 2.
3
Fluoroquinolone efflux mediated by ABC transporters.由ABC转运蛋白介导的氟喹诺酮外排
J Pharm Sci. 2008 Sep;97(9):3483-93. doi: 10.1002/jps.21233.
4
P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers.人肺泡上皮细胞单层中的P-糖蛋白（MDR1）功能活性
Cell Tissue Res. 2007 Apr;328(1):77-84. doi: 10.1007/s00441-006-0346-6. Epub 2006 Dec 13.
5
Protonation equilibrium and lipophilicity of moxifloxacin.莫西沙星的质子化平衡与亲脂性
J Pharm Biomed Anal. 2005 Feb 23;37(2):389-93. doi: 10.1016/j.jpba.2004.10.022.
6
Transport characteristics of fexofenadine in the Caco-2 cell model.非索非那定在Caco-2细胞模型中的转运特性。
Pharm Res. 2004 Aug;21(8):1398-404. doi: 10.1023/b:pham.0000036913.90332.b1.
7
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers.外排比率无法评估P-糖蛋白介导的吸收性转运减弱：P-糖蛋白对跨Caco-2细胞单层吸收性和分泌性转运的不对称效应。
Pharm Res. 2003 Aug;20(8):1200-9. doi: 10.1023/a:1025049014674.
8
Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.格帕沙星和左氧氟沙星在人肠上皮细胞系Caco-2中的转运特性
Eur J Pharmacol. 2001 Nov 23;431(3):297-303. doi: 10.1016/s0014-2999(01)01448-0.
9
Multidrug resistance-associated protein-1 functional activity in Calu-3 cells.
J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
10
Pharmacokinetics of pefloxacin in renal insufficiency.培氟沙星在肾功能不全患者中的药代动力学
Eur J Clin Pharmacol. 1985;29(3):345-9. doi: 10.1007/BF00544092.
Zotero 插件